FINWIRES · TerminalLIVE
FINWIRES

HKG:2595

4 stories mentioning HKG:2595Updated 3d ago

Every FINWIRES story that references HKG:2595, newest first.

Asia

GenFleet Therapeutics's Lung Cancer Drug Advances in Phase 3 Trial, First Patient Dosed

GenFleet Therapeutics (Shanghai)'s (HKG:2595) GFH375 advanced into a registrational phase III study in China, according to a Monday Hong Kong bourse filing.The trial will be conducted across over 40 sites nationwide, with the first patient recently dosed at Nanjing Drum Tower Hospital.The trial will evaluate monotherapy efficacy and safety versus docetaxel in patients with KRAS G12D-mutant locally advanced, unresectable, or metastatic non-small cell lung cancer who have failed standard-of-care therapy.

HKG:2595
Asia

GenFleet Therapeutics Seeks HK$467 Million via H-Share Placement; Shares Up 11%

GenFleet Therapeutics (Shanghai) (HKG:2595) is seeking to raise net proceeds of about HK$466.9 million through the placement of 13.6 million new H-shares, according to a Hong Kong bourse filing on Wednesday.The company is offering the shares at HK$34.69 each, representing a 9.71% discount to the last closing price.The net proceeds will primarily be used to advance the clinical development of its RAS inhibitor pipeline, enhance its research and development platforms, and for working capital and general corporate purposes.The new shares represent about 3.67% of the company's existing issued share capital and about 3.54% of its enlarged share capital after the placement.Shares of the biopharmaceutical company were up over 11% in Wednesday afternoon trade.

HKG:2595
Asia

GenFleet Therapeutics Launches Share Buyback

GenFleet Therapeutics (Shanghai) (HKG:2595) is proposing to buy back up to HK$350 million Hong Kong-listed shares, according to a Monday Hong Kong bourse filing.The biopharmaceutical company will repurchase the shares from the open market from time to time.

HKG:2595
Asia

GenFleet Therapeutics Says RAS Inhibitor Program Unrelated to RevMed IP Dispute; Shares Down 7%

GenFleet Therapeutics (Shanghai) (HKG:2595) said correspondence issued by Revolution Medicines on patent and trade secret disputes over RAS inhibitors is unrelated to the company, according to a Tuesday Hong Kong bourse filing.GenFleet said all entities, products, and disputed matters referenced are "entirely unrelated" to it.The company added GFH276, which is developed on fully independent, original, and proprietary intellectual property, with no exposure to such risks.The company said it has built a global patent portfolio for its Pan RAS inhibitor program, with the core patent for GFH276's compound structure published on March 6, 2025, and protection expected to extend to 2044.GenFleet's shares fell nearly 7% in recent trade.

HKG:2595

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2595 in your portfolio
WheelAI
WheelAI
Analyze HKG:2595 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2595